ash 2025

Dr. Juan Du presented early phase one study findings at ASH 2025, detailing a novel dual-targeted FasTCAR-T therapy for newly diagnosed multiple myeloma. The study demonstrated deep, durable responses in patients using the BCMA and CD19-targeting CAR T-cell platform, GC012F/AZD0120. These promising results, consistent across all dose groups, highlight a highly favorable safety profile and potential for patients, including those with high-risk features and transplant-ineligible individuals.

Wojciech Jurczak MD PhD discusses research from ASH 2025, revealing that the non-covalent BTK inhibitor pirtobrutinib is superior to bendamustine plus rituximab as initial therapy for untreated chronic lymphocytic leukemia and small lymphocytic lymphoma. The BRUIN CLL-313 phase 3 study found pirtobrutinib significantly improved progression-free survival and was well-tolerated. These data suggest pirtobrutinib could become a new standard of care for these patients.

This episode discusses how the bispecific antibody Epcoritamab, in combination with rituximab and lenalidomide, has outperformed standard treatment for relapsed/refractory follicular lymphoma in the phase three epcore FL-1 trial. Dr. Lorenzo Falchi, an attending physician at Memorial Sloan Kettering, was interviewed at the ASH 2025 Annual Meeting, where these significant findings, including improved ORR and PFS, were presented, demonstrating a substantial reduction in the risk of progression or

Antonio Jimenez Jimenez MD MS, from the University of Miami, presented findings at ASH 2025 indicating that donor choice is less of a barrier to allogeneic stem cell transplantation for patients with hematologic malignancies. The National Marrow Donor Program Access Trial found that post-transplant cyclophosphamide enables a wider, more ethnically diverse range of patients to safely receive transplants from unrelated donors.

Dr. Luciano Costa discusses the findings from the CARTITUDE-4 study at the ASH 2025 Annual Meeting in Orlando. The study demonstrates that ciltacabtagene autoleucel CAR-T cell therapy provides significant long-term progression-free survival for patients with standard-risk relapsed or refractory multiple myeloma, even as early as second-line treatment. The findings suggest profound benefits in this patient population.

Dr. Jesse Tettero discusses findings from the HARMONY Alliance study, presented at ASH 2025, validating measurable residual disease (MRD) as a robust predictor of overall survival in acute myeloid leukemia (AML) patients. The study supports MRD's potential as a regulatory surrogate endpoint, particularly MFC-MRD in non-transplanted patients, to accelerate drug development. This large pooled analysis provides critical evidence for future AML drug approvals.

Dr. Hisham Abdel-Azim discusses findings from the phase two EndRAD trial, presented at ASH 2025. The study reveals that Next Generation Sequencing-Assessed Minimum Residual Disease (NGS-MRD) can identify young patients with high-risk/relapsed B-cell Acute Lymphoblastic Lymphomas (B-ALL) who can safely omit pre-transplant Total Body Irradiation (TBI). This approach achieved comparable survival outcomes while potentially reducing TBI-associated late effects.